IRAK4 Biology and Target Rationale
                                                                                                      IRAK4
                                                                                                  SCAFFOLDING
                                                                                                     KINASE


Target Rationale                                                                            IL-1R/TLR Pathway
•   IRAK4 is an obligate node in IL-1R/TLR signaling, and its degradation is            TLR
                                                                                                                        Cytokines
                                                                                                                        IL-1, IL-18,
    the only approach to fully block the pathway                                      Agonists
                                                                                                                       IL-33, IL-36

                                                                                           TLRs                           IL-1R
Human Genetics
•   Adult humans with IRAK4 null mutation are healthy

                                                                               Cytoplasm
Clinical Pathway Validation                                                                               MyD88
•   IRAK4 degradation has the potential to achieve a broad, well-tolerated
                                                                                                          IRAK4
    anti-inflammatory effect                                                          KT-485                         Myddosome
                                                                                                          IRAK1/2
•   Multiple development opportunities in immune-inflammatory diseases
                                                                                                          TRAF6
    which signal through MyD88/IRAK4 have been clinically validated1:                         Catalytic              Scaffolding
      • IL-1⍺/IL-1b: RA, CAPS, HS, AD, RP, Gout
                                                                                                     Th1/Th2/Th17
      • IL-18: AD, Macrophage Activation Syndrome                                                     Inflammation
      • IL-36: Generalized Pustular Psoriasis
      • IL-33: Asthma, COPD                                                          IRAK4 is master regulator of
      • IRAK4 SMI: RA                                                                innate immunity with
                                                                                     scaffolding and kinase functions


                                                                                                                                       64
